Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCONE Study in atypical hemolytic uremic syndrome
NL-OMON37013Active, not recruiting
- Sponsor
- Nederlandse Federatie van Universitair Medische Centra
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of eculizumab in atypical hemolytic uremic syndrome (aHUS) (3 cohorts), sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoints: C3 level, C3b level and 12 more. Started Dec 2012; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NL-OMON37013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37013.